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Background
Birch pollen-allergic subjects often develop Bet v 1-specific
IgE that cross-reacts with homologous food allergens. Bet
v 1 and its homologs in pollen and food display exclusively
conformational epitopes. We established a system to spe-
cifically analyze epitope cross-reactivity of Bet v 1-related
allergens. The enzyme norcoclaurine synthase (NCS) from
Thalictrum flavum is structurally homologous to Bet v 1
but does not bind IgE reacting with Bet v 1-like allergens.
By substituting amino acids in a variant of NCS, the
impact of individual residues of Bet v 1-like allergens in
IgE binding can be studied.
Methods
Residues potentially involved in IgE binding of Bet v 1
were inserted into NCS. NCS variants were purified and
protein secondary and tertiary structures were evaluated
by CD and NMR spectroscopy. Sera of birch pollen aller-
gic patients were analyzed for IgE binding to NCS variants
and Bet v 1-like food allergens. Cross-reactivity of patients’
IgE was assessed by competitive binding assays using var-
iants of NCS and Bet v 1 as well as Cor a 1, Dau c 1, Api g
1, Pru av 1, and Gly m 4, respectively.
Results
CD spectra and 1H15N-HSQC NMR indicated Bet v 1-like
structure of NCS variants. sIgE binding increased signifi-
cantly with the number of amino acids substituted in NCS
from ≤ 0.35 kUA/L in 94% (65/69) of sera to CAP values
up to 17.4 kUA/L for NCSN57/I58E/D60N/V63P/D68K (NCS_5x)
in 68% (47/69) of sera. IgE interaction of NCS_5x could be
competitively inhibited with Bet v 1, Cor a 1, and Gly m 4,
whereas strongly reduced inhibition was observed with Bet
v 1N43A/E45S/N47A/K55A, Api g 1, Pru av 1, and Dau c 1,
respectively. Structural analysis of the IgE-binding site of
NCS_5x showed high conformational similarity with Bet v
1, Cor a 1 and Gly m 4 and low similarity with Pru av 1,
Api g 1, and Dau c 1, respectively. Murine monoclonal
antibody BV16 abolished Bet v 1-specific inhibition of IgE
binding to NCS_5x indicating an overlap between an IgE
and IgG epitope.
Conclusions
Five residues critical for IgE cross-reactivity in a subgroup
of Bet v 1-like allergens were identified. NCS_5x bound
IgE that cross-reacted only with Bet v 1-related allergens
sharing an epitope structure similar to that of NCS_5x.
Thus non-allergenic NCS with its Bet v 1-homologous
structure is a powerful system for the residue-specific ana-
lysis of epitopes of Bet v 1-related allergens.
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